Among people with rare mutations in the CFTR gene, the gene defective in cystic fibrosis (CF), studies are needed to…
Magdalena Kegel
Magdalena is a writer with a passion for bridging the gap between the people performing research, and those who want or need to understand it. She writes about medical science and drug discovery. She holds an MS in Pharmaceutical Bioscience and a PhD — spanning the fields of psychiatry, immunology, and neuropharmacology — from Karolinska Institutet in Sweden.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Magdalena Kegel
Liver disease in cystic fibrosis (CF) patients needs to be detected much earlier, but early detection is increasingly likely as research…
Abnormal mucus clearance in patients with cystic fibrosis (CF) may be improved with specific treatments, but despite intense research on…
#NACFC2016 – CF Patients Benefit from Home Tai Chi Training Using Video Calls, Face-to-Face Sessions
Tai chi, taught either in face-to-face home sessions or using internet-based video calls, improved ease of breathing and posture in cystic…
Cystic fibrosis (CF) patients carrying the F508del mutation in both CFTR gene copies maintained their lung function during more than…
According to a new study, acute exacerbations of cystic fibrosis (CF) are associated with a surge of bacteria that do…
Researchers at the Perelman School of Medicine at the University of Pennsylvania, Cincinnati Children’s Hospital and Boston…
The experimental drug Translarna (ataluren) can make the cellular protein-making machinery run the so-called “stop sign” mutation in the…
Toxins produced by mold found on nuts and corn can exacerbate cystic fibrosis (CF) and pave the way for airway…
Arch Biopartners and Catalent Inhalation, a division of Catalent Pharma Solutions, have entered agreements to start manufacturing AB569 for human trials…